Tenaya Therapeutics (TNYA) director June Lee granted 120,000 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. director June Lee received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $0.7989 per share and were granted as compensation, not through an open-market purchase.

The options will vest in full on May 28, 2027, or earlier on the day immediately before the next annual stockholder meeting after the grant date, as long as Lee continues as a service provider to the company. The options expire on May 27, 2036, and following this grant Lee holds 120,000 options in total.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lee June

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	120,000	$0.00	--

Holdings After Transaction: Stock Option (Right to buy) — 120,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 120,000 options Exercise price: $0.7989 per share Underlying shares: 120,000 shares +3 more

6 metrics

Options granted 120,000 options Stock Option (Right to buy) grant to director June Lee

Exercise price $0.7989 per share Exercise price for the 120,000 stock options

Underlying shares 120,000 shares Common stock underlying the granted options

Vesting date May 28, 2027 Scheduled full vesting date, subject to continued service

Expiration date May 27, 2036 Option expiration date

Holdings after grant 120,000 options Total options held by June Lee following this grant

Key Terms

Stock Option (Right to buy), Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan, vesting, service provider

4 terms

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan financial

"Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan."

vesting financial

"Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

service provider financial

"subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 05/29/2026 - 07:09 PM Accepted by SEC EDGAR 05/29/2026 - 07:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee June

(Last)

(First)

(Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to buy)	$0.7989	05/28/2026		A		120,000		05/28/2027⁽¹⁾	05/27/2036	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did June Lee report in this Form 4 for Tenaya Therapeutics (TNYA)?

June Lee reported receiving a grant of stock options for 120,000 shares of Tenaya Therapeutics common stock. The options were awarded as compensation under the company’s 2021 Equity Incentive Plan at an exercise price of $0.7989 per share.

What is the exercise price of June Lee’s new Tenaya Therapeutics (TNYA) options?

The stock options granted to June Lee have an exercise price of $0.7989 per share. This means Lee can buy Tenaya Therapeutics common stock at $0.7989 once the options vest and before they expire, subject to continued service conditions.

When do June Lee’s Tenaya Therapeutics (TNYA) stock options vest?

The options are scheduled to vest in full on May 28, 2027. They may vest earlier on the day immediately before the next annual meeting of stockholders after the grant date, if Lee continues as a service provider through that time.

When do June Lee’s Tenaya Therapeutics (TNYA) stock options expire?

The options granted to June Lee expire on May 27, 2036. Lee must exercise any vested options before that expiration date to acquire Tenaya Therapeutics common stock at the $0.7989 exercise price.

How many Tenaya Therapeutics (TNYA) options does June Lee hold after this grant?

Following this transaction, June Lee holds 120,000 stock options. All of these options relate to Tenaya Therapeutics common stock and were acquired in this single grant reported in the Form 4 filing.

Is June Lee’s Form 4 transaction a market purchase of Tenaya Therapeutics (TNYA) shares?

No, the transaction is a grant of stock options as compensation, not a market purchase. The options were issued with a $0.7989 exercise price under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.